LSBC scores a minor contracting win. Staying afloat, but not prospering . . .
>>VACAVILLE, CA--(MARKET WIRE)--Jul 15, 2004 -- Large Scale Biology Corporation (NasdaqNM:LSBC - News) and privately held Planet Biotechnology Inc., (Planet) of Hayward, California, today announced initiation of a biomanufacturing agreement to extract and purify Planet's lead product, CaroRx(TM), a plant-made antibody to control dental caries.
Planet's CaroRx(TM) is the world's first recombinant plant-made antibody to be clinically tested, and has been shown to prevent the adhesion of tooth decay causing bacteria to the tooth surface. Planet's tobacco plants expressing CaroRx(TM) secretory IgA will be extracted by LSBC at its Owensboro, Kentucky, manufacturing facility. CaroRx(TM) has completed Phase I clinical trials under an approved U.S. FDA Investigational New Drug (IND) application.
"The experience and manufacturing capabilities that LSBC offers in the area of plant-produced recombinant protein extraction complements our proprietary gene expression and product development technologies," stated Elliott Fineman, President and CEO of Planet Biotechnology. "Larger quantities of CaroRx(TM) are needed for our expanded clinical trials, and testing of formulations for the European market. We are happy to be working with LSBC during the scale-up phase of product development," Mr. Fineman added.
"We are pleased to be working with Planet, a true pioneer in the development of plant-produced antibodies, as they expand their development program for their exciting new product, CaroRx(TM)," said Kevin Ryan, LSBC's President and CEO. "Our new agreement with Planet further exemplifies LSBC's leadership role in the manufacture of plant-made pharmaceuticals and demonstrates the versatility of our Owensboro manufacturing facility in the extraction of a wide range of products," Mr. Ryan added.<<
snip
Cheers, Tuck |
